LJ-2698

Synonyms: FM101
LJ-2698 (FM101) 是一种具有口服活性的腺苷 A3 受体 (Adenosine A3 Receptor) 拮抗剂,可阻断腺苷 A3 受体依赖性促炎 JNK、ERK、NF-κB 信号通路,阻止小鼠肺泡腔扩大、恢复小鼠肺功能、抑制小鼠肺组织中的基质金属蛋白酶活性与肺细胞凋亡 (apoptosis),并可诱导线粒体功能障碍、坏死性凋亡 (necroptosis) 及内源性凋亡,还能改变糖尿病肾病小鼠肾损伤、缓解饮食诱导的肝脏炎症与纤维化,可用于肺气肿、糖尿病肾病及代谢功能障碍相关脂肪性肝病的研究。
产品编号: MS-R42013 CAS No.: 945457-84-1 分子式: C16H15Cl2N5O2S 分子量: 412.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

LJ-2698 (FM101) 是一种具有口服活性的腺苷 A3 受体 (Adenosine A3 Receptor) 拮抗剂,可阻断腺苷 A3 受体依赖性促炎 JNK、ERK、NF-κB 信号通路,阻止小鼠肺泡腔扩大、恢复小鼠肺功能、抑制小鼠肺组织中的基质金属蛋白酶活性与肺细胞凋亡 (apoptosis),并可诱导线粒体功能障碍、坏死性凋亡 (necroptosis) 及内源性凋亡,还能改变糖尿病肾病小鼠肾损伤、缓解饮食诱导的肝脏炎症与纤维化,可用于肺气肿、糖尿病肾病及代谢功能障碍相关脂肪性肝病的研究。

生物实验数据

生物活性 LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist that blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways, prevents alveolar space enlargement, restores lung function, and inhibits matrix metalloproteinase activity and apoptosis in mouse lung tissue, while also inducing mitochondrial dysfunction, necroptosis, and intrinsic apoptosis, and ameliorating renal injury in diabetic nephropathy mice and diet-induced hepatic inflammation and fibrosis, making it useful for research on emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease.
体外研究
(In Vitro)

LJ-2698 (0.1 μM、72 h) 可恢复 LPS (MS-X54539) 刺激的 RAW 264.7 小鼠巨噬细胞中抗炎细胞因子 (Il4、Il10) 及 M2 型巨噬细胞标志物 (Arg1、Mrc1) 的表达。
LJ-2698 (1 μM) 可强效且选择性地抑制 A3AR,抑制率达 88%。
LJ-2698 (2-4 μM; 6 h) 可诱导 LPS 刺激的 ImKC 中由 β-arrestin2 介导的 A3AR 溶酶体降解,并抑制依赖 A3AR 的促炎信号通路,包括 JNK、ERK 和 NF-κB。
LJ-2698 (2-4 μM; 6-24 h) 可通过下调促炎细胞因子基因表达及 TNF-α 分泌,在 LPS 刺激的原代小鼠库普弗细胞和 THP-1 人巨噬样细胞中发挥抗炎作用。
LJ-2698 (4 μM) 可诱导原代小鼠枯否细胞、HeLa 细胞及 LPS 刺激的 ImKC 发生线粒体功能障碍,包括呼吸受抑制、ATP 生成减少、受损线粒体增多以及线粒体超氧化物水平升高,且其抗炎作用依赖于线粒体完整性。
LJ-2698 (4 μM; 12 h) 可通过激活 p53/AKT1/GSK3β/β-catenin 信号级联反应,在 LPS 刺激的 ImKC 中以坏死性凋亡作为主导细胞死亡途径,同时诱导轻度的内源性凋亡,并抑制焦亡和外源性凋亡。
LJ-2698 (4 μM; 24 h) 可选择性地在 LPS 刺激的 ImKC 和 PA 处理的肝细胞中诱导细胞毒性,但在未受刺激的 ImKC、HSC 或 BSA 处理的肝细胞中无此作用。
LJ-2698 (4 μM; 12 h) 可通过下调促炎基因表达、上调细胞死亡相关基因表达并诱导细胞毒性,选择性靶向促炎性单核细胞来源库普弗细胞 (MoKCs),同时不影响胚胎来源库普弗细胞 (EmKCs)。

Real Time qPCR

Cell Line: RAW 264.7 (murine macrophage)
Concentration: 0.1 μM
Incubation Time: 48 h (pretreatment); 24 h (co-incubation with LPS)
Result: Significantly ameliorated LPS-mediated downregulation of Il4 and Il10 anti-inflammatory cytokine mRNA expression.
Significantly restored LPS-mediated downregulation of Arg1 and Mrc1 M2 macrophage marker mRNA expression.

Western Blot Analysis

Cell Line: immortalized mouse Kupffer cells (ImKCs)
Concentration: 2 μM, 4 μM, 4 μM (with wortmannin)
Incubation Time: 6 h (2 μM, 4 μM); treatment duration not specified (4 μM with wortmannin)
Result: Reduced A3AR and β-arrestin2 protein levels significantly in LPS-stimulated ImKCs.
Left β-arrestin1 levels unchanged.
Rescued A3AR and β-arrestin2 protein levels when co-treated with wortmannin.
Showed a strong positive correlation between A3AR and β-arrestin2 protein expression.
Reduced levels of phosphorylated JNK, ERK, and IκB-α significantly in LPS-stimulated ImKCs.

Western Blot Analysis

Cell Line: immortalized mouse Kupffer cells (ImKCs)
Concentration: 4 μM
Incubation Time: 12 h
Result: Activated the p53/AKT1/GSK3β/β-catenin signaling cascade in LPS-stimulated ImKCs.
Elevated levels of phosphorylated RIP3 and MLKL (key necroptosis markers) markedly.
Increased cleaved caspase-3 (intrinsic apoptosis marker).
Decreased cleaved caspase-8, caspase-7, caspase-1, and GSDMD (pyroptosis and extrinsic apoptosis markers).
体内研究
(In Vivo)

LJ-2698 (50 μg/kg;灌胃;每周 6 次;持续 5 周) 可通过恢复肺功能、减少气腔扩大、抑制基质金属蛋白酶活性及肺细胞凋亡、促进 M2 巨噬细胞介导的抗炎反应,显著抑制 Elastase, Porcine pancreas (MS-R62000) 诱导的 FVB 小鼠肺气肿,且观察到的毒性极低。
LJ-2698 (1.5-10 mg/kg;口服;每日;12 周) 每日口服给药 12 周,可呈剂量依赖性改善 db/db 小鼠的糖尿病肾病,其中 10 mg/kg 剂量在所有检测指标中均展现出最稳定且全面的肾脏保护作用。
FM101 (30-60 mg/kg;口服;每日;6 周) 以 30 或 60 mg/kg 的剂量每日给药、持续 6 周,可通过减轻肝脏炎症、纤维化及促炎单核细胞来源的库普弗细胞数量,改善 FFD 诱导的 C57BL/6 N 小鼠 MASLD;其中 60 mg/kg 剂量还可降低肝脏重量及肝体比。

Animal Model: FVB mice (8-week-old)
Dosage: 50 μg/kg
Administration: p.o.; 6 times per week; 5 weeks
Result: Restored lung compliance and tissue elasticity to levels closer to control mice.
Markedly suppressed PPE-induced airspace enlargement and reduced the elevated PPE-induced mean linear intercept (MLI).
Suppressed PPE-mediated increases in matrix metalloproteinase gelatinase activity in lung tissue.
Significantly reduced the number of TUNEL-positive apoptotic cells in the lungs compared to PPE-only treated mice.
Restored PPE-induced downregulation of anti-inflammatory cytokine (Il4, Il10) and M2 macrophage marker (Arg1, Mrc1/CD206) mRNA expression in lung tissue.
Increased the number of CD206-positive M2 macrophages per field in lung tissue.
Caused no significant changes in body weight compared to control or PPE-only groups, indicating minimal toxicity.
Animal Model: C57BLKS/J-db/db (male, 8 weeks old)
Dosage: 1.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; daily; 12 weeks
Result: Significantly reduced elevated glomerular volume and fractional mesangial area across all three doses, with no significant differences between doses.
Significantly reduced increased urinary albumin excretion at 5 and 10 mg/kg doses; did not produce a significant reduction at 1.5 mg/kg dose.
Significantly prevented reduced nephrin mRNA levels and increased NGAL mRNA levels at 10 mg/kg dose.
Significantly inhibited increased TGF-β mRNA levels at 10 mg/kg dose; did not produce a significant reduction at 1.5 and 5 mg/kg doses.
Significantly reduced increased collagen IV and fibronectin mRNA levels at 5 and 10 mg/kg doses.
Significantly reduced elevated MCP-1 mRNA levels at 5 and 10 mg/kg doses; significantly inhibited increased ICAM-1 mRNA levels at 10 mg/kg dose, while 1.5 and 5 mg/kg doses did not.
Significantly decreased increased urinary LPO levels at 5 and 10 mg/kg doses.
Animal Model: C57BL/6N (age 8 weeks at study start; fed high-fat, high-cholesterol fast-food diet with fructose and glucose in drinking water for 24 weeks)
Dosage: 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 6 weeks
Result: Significantly reduced body weight, serum alanine aminotransferase (ALT) levels, serum cholesterol levels, NAFLD Activity Score, hepatic collagen deposition (Sirius Red-positive area), mRNA expression of pro-inflammatory genes (Ccl2, Ccl3, Cxcl2), mRNA expression of profibrogenic genes (Col1a1, Col1a4, Lox, Timp1), hepatic levels of phosphorylated AKT, JNK, and P65, and the percentage of CLEC4F-positive Kupffer cells at 30 mg/kg dose compared to FFD-fed vehicle controls.
Significantly reduced body weight, liver weight, liver-to-body weight ratio, serum ALT levels, serum cholesterol levels, NAFLD Activity Score, hepatic collagen deposition (Sirius Red-positive area), mRNA expression of pro-inflammatory genes (Ccl2, Ccl3, Cxcl2), mRNA expression of profibrogenic genes (Col1a1, Col1a4, Lox, Timp1), hepatic levels of phosphorylated AKT, JNK, and P65, and the percentage of CLEC4F-positive Kupffer cells at 60 mg/kg dose compared to FFD-fed vehicle controls.

化学信息

分子量 412.29
分子式 C16H15Cl2N5O2S
CAS No. 945457-84-1
别名 FM101

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础